Nitika Sharma, MD
Hematology & Oncology · Newnan, GANPI 1043631773
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,960 of the $6,603 with a category attached, or 75.1%. Stemline Therapeutics Inc. accounts for 75.1% of it on its own, with 31 other manufacturers making up the rest. 2025 is the largest year on record at $4,960, 4.0 times the $1,237 reported in 2019.
Across 111 payments — averaging $59.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stemline Therapeutics Inc.$5K
- E.r. Squibb & Sons, L.L.C.$261
- Merck$230
- AstraZeneca$174
- Genentech USA, Inc.$81
- Bristol Myers Squibb$74
- plus $823 from 26 others
Across 13 payments — averaging $31,112 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$185K
- Merck$164K
- AstraZeneca$45K
- Pfizer$10K
What the payments were for
- Consulting fees$4,96075%
- Food & beverage$1,64325%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stemline Therapeutics Inc. | 2 | $4,960 |
| E.r. Squibb & Sons, L.L.C. | 20 | $261 |
| Merck | 16 | $230 |
| AstraZeneca(2 entities) | 11 | $174 |
| Genentech USA, Inc. | 6 | $81 |
| Bristol Myers Squibb | 4 | $74 |
| Novartis | 4 | $71 |
| Pfizer | 5 | $67 |
| Amgen | 4 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $61 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $56 |
| Boehringer Ingelheim | 3 | $52 |
| Bayer | 3 | $51 |
| Lilly USA, LLC | 3 | $43 |
| Gilead | 2 | $36 |
| Exelixis Inc. | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 2 | $33 |
| Seagen Inc. | 2 | $29 |
| Myriad Genetic Laboratories, Inc. | 1 | $21 |
| Coherus Oncology, Inc. | 1 | $20 |
| Tesaro, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Sanofi | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $15 |
| BTG International Inc. | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Kyowa Kirin, Inc. | 1 | $12 |
| EMD Serono, Inc. | 1 | $11 |
| Secura Bio, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orserdu$4,960
How this compares
$6,603 in reported general payments places this provider in the 55th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 50 | $754,411 |
| IbrancePalbociclib | 35 | $556,521 |
| TagrissoOsimertinib Mesylate | 21 | $346,697 |
| TruqapCapivasertib | 14 | $280,479 |
| KisqaliRibociclib Succinate | 11 | $138,653 |
| Everolimus | 15 | $102,541 |
| ZarxioFilgrastim-Sndz | 19 | $22,469 |
| EliquisApixaban | 25 | $13,284 |
| XareltoRivaroxaban | 14 | $8,071 |
| Exemestane | 38 | $7,933 |
| Anastrozole | 155 | $2,415 |
| Tamoxifen Citrate | 107 | $2,198 |
| Letrozole | 103 | $1,867 |
| Fulvestrant | 11 | $1,425 |
| Potassium Chloride | 58 | $1,168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio, Olanzapine | $43 | $754,59569 claims |
| AstraZenecaTagrisso, Truqap | $174 | $627,17635 claims |
| PfizerIbrance, Eliquis | $67 | $569,80560 claims |
| NovartisKisqali | $71 | $138,65311 claims |
| Johnson & JohnsonXarelto | $17 | $8,07114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Newnan
- Vasileios AssikisNewnan$62K
- Bamidele AdesunloyeNewnan$38K
- Priya RudolphAthens$745K
- Aron KefelaHiram$591K
- Chandar BhimaniConyers$483K
- Ticiana LealAtlanta$450K
- Steven McCuneMarietta$450K
- Jorge LeguizamoLawrenceville$409K
- Trevor FeinsteinFayetteville$341K
- Jigarkumar ParikhAugusta$267K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.